Radiotherapy
Comparison of the efficacy of stereotactic body radiotherapy and surgery for intrapulmonary recurrence patients after non-small cell lung cancer surgery
Wu Qing, Dong Baiqiang, Jin Jianan, Hang Qingqing, Liu Xiaohui, Xu Yujin, Chen Ming
Published 2022-11-25
Cite as Chin J Radiol Med Prot, 2022, 42(11): 857-864. DOI: 10.3760/cma.j.cn112271-20220702-00277
Abstract
ObjectiveTo compare the efficacy of stereotactic body radiotherapy(SBRT) and surgery in treating intrapulmonary recurrence of non-small cell lung cancer (NSCLC) after radical surgery.
MethodsA retrospective analysis was conducted on NSCLC patients, who underwent radical surgery at the Cancer Hospital Affiliated to University of Chinese Academy of Sciences from November 2012 to December 2018 and then received SBRT or secondary surgery because of postoperative intrapulmonary recurrence. The survival rates of these patients were calculated using the Kaplan-Meier method. The comparison between the two groups was made using the Log-rank method, and the univariate and multivariate analysis was made using the Cox regression method.
ResultsAmong 62 eligible patients, 33 received SBRT and 29 received secondary surgery, and they were divided into the SBRT group and the surgery group accordingly. For the SBRT and surgery groups, the median follow-up time was 45.8 months and 37.4 months, the 3-year locoregional control rate (LRCR) 79.8% and 90.2%, respectively (P > 0.05), the progression-free-survival (PFS) 58.5% and 42.3%, respectively (P >0.05), and the overall survival (OS) 78.0% and 85.5%, respectively (P >0.05). The multivariate analysis suggested that treatment method, Charlson comorbidity index (CCI), and adjuvant drug therapy were independent prognostic factors for PFS (P = 0.027, 0.013, 0.001).
ConclusionsThe efficacy of SBRT and surgery is comparable for patients with intrapulmonary recurrence of NSCLC after radical surgery.
Key words:
Non-small cell lung cancer; Stereotactic body radiation therapy; Surgical treatment; Intrapulmonary recurrence
Contributor Information
Wu Qing
The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou 310053, China
Dong Baiqiang
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
Jin Jianan
Phase I Clinical Trial Ward, Cancer Hospital Affiliated to University of Chinese Academy of Science, Zhejiang Cancer Hospital, Hangzhou 310022, China
Hang Qingqing
The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou 310053, China
Liu Xiaohui
The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou 310053, China
Xu Yujin
Department of Chest Radiotherapy, Cancer Hospital Affiliated to University of Chinese Academy of Science, Zhejiang Cancer Hospital, Hangzhou 310022, China
Chen Ming
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
